Theresa Greco's blog
Healthy Data Webinar – Check in on the checkup for the Sunshine Act
After a well-attended session at CBI's 5th Annual Tracking State Laws and Aggregate Spend , Health Market Science and CBI decided to create a follow-up webinar that echoes some points offered in my August presentation, while offering more detail on the cost of poor quality data.
Q: Is the industry ready to comply with aggregate spend regs? A: Surprisingly, maybe not.
As a speaker at the CBI Aggregate Spend Conference last week, (with a timely agenda and a great turnout) I was looking forward to gauging Life Science organizations’ response to what will soon be the final regs of the Sunshine Act. I was quickly enlightened. With the first session, I could tell participants were still learning the options for overcoming the challenges of transparency. In fact, some are still in the planning stage!
The Pharma C-Suite is under increased scrutiny from the feds. Why should it have to get personal?
The recent Associated Press article, In shift, feds target top execs for health fraud, may rattle some chains in healthcare’s C-suite. In the article, the author suggests that “Federal enforcers are targeting individual executives in health care fraud cases that used to be aimed at impersonal corporations.” The notion of holding executives accountable has grown since the economic recession.
